These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 33973876)

  • 1. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
    Keene CM; Griesel R; Zhao Y; Gcwabe Z; Sayed K; Hill A; Cassidy T; Ngwenya O; Jackson A; van Zyl G; Schutz C; Goliath R; Flowers T; Goemaere E; Wiesner L; Simmons B; Maartens G; Meintjes G
    AIDS; 2021 Jul; 35(9):1423-1432. PubMed ID: 33973876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
    Keene CM; Cassidy T; Zhao Y; Griesel R; Jackson A; Sayed K; Omar Z; Hill A; Ngwenya O; Van Zyl G; Flowers T; Goemaere E; Maartens G; Meintjes G
    J Acquir Immune Defic Syndr; 2023 Apr; 92(5):422-429. PubMed ID: 36706364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
    Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
    Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
    Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
    Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
    Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
    J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.
    Luwaya EL; Mwape L; Bwalya K; Siakabanze C; Hamooya BM; Masenga SK
    PLoS One; 2024; 19(9):e0308869. PubMed ID: 39241081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies.
    Ait-Khaled M; Sierra Madero J; Estrada V; Gulminetti R; Hagins D; Tsai HC; Man C; Sievers J; Grove R; Zolopa A; Wynne B; van Wyk J
    HIV Res Clin Pract; 2021 Dec; 23(1):9-14. PubMed ID: 34913844
    [No Abstract]   [Full Text] [Related]  

  • 11. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.
    Underwood M; Urbaityte R; Wang R; Horton J; Oyee J; Wynne B; Fox D; Jones B; Man C; Sievers J
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial.
    Zhao Y; Keene C; Griesel R; Sayed K; Gcwabe Z; Jackson A; Ngwenya O; Schutz C; Goliath R; Cassidy T; Goemaere E; Hill A; Maartens G; Meintjes G
    Wellcome Open Res; 2021; 6():33. PubMed ID: 36017341
    [No Abstract]   [Full Text] [Related]  

  • 14. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
    De Miguel R; Rial-Crestelo D; Dominguez-Dominguez L; Montejano R; Esteban-Cantos A; Aranguren-Rivas P; Stella-Ascariz N; Bisbal O; Bermejo-Plaza L; Garcia-Alvarez M; Alejos B; Hernando A; Santacreu-Guerrero M; Cadiñanos J; Mayoral M; Castro JM; Moreno V; Martin-Carbonero L; Delgado R; Rubio R; Pulido F; Arribas JR;
    EBioMedicine; 2020 May; 55():102779. PubMed ID: 32408111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Tenorio AR; Pappa KA; Wynne B; Gartland M; Aboud M; van Wyk J; Smith KY
    J Acquir Immune Defic Syndr; 2020 Mar; 83(3):310-318. PubMed ID: 31834000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results.
    McCluskey SM; Muyindike WR; Nanfuka V; Omoding D; Komukama N; Barigye IT; Kansiime L; Tumusiime J; Aung TN; Stuckwisch A; Hedt-Gauthier B; Marconi VC; Moosa MS; Pillay D; Giandhari J; Lessells R; Gupta RK; Siedner MJ
    J Infect Dis; 2024 Sep; 230(3):e622-e630. PubMed ID: 38748986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
    van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    van Heerden JK; Meintjes G; Barr D; Zhao Y; Griesel R; Keene CM; Wiesner L; Galileya LT; Denti P; Maartens G
    J Acquir Immune Defic Syndr; 2024 Mar; 95(3):260-267. PubMed ID: 38408216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.